🧪 Huntsman (HUN): CEO Buys $981K as Wall Street Overlooks a $12 Billion Chemical Merger

Inside the Olin Merger, $400M Synergies, 0.64x Book Value, 107% Institutional Lockup, and Why Management Keeps Buying 🧪🔥

Is Huntsman a Value Trap—or One of the Market's Most Overlooked Industrial Turnaround Stories?

IONS

$10.02
NYSE: HUN
+0.26 (+2.66%)
As of Aug. 3, 2026, 4:10 PM ET

There are insider purchases...

...and then there are CEO conviction purchases.

When a chief executive quietly spends nearly $1 million of his own money buying shares of the company he already runs, investors should at least pause before dismissing the stock as "just another struggling cyclical."

That is precisely what happened at Huntsman Corporation (NYSE: HUN).

On August 3, 2026, Chairman, President and CEO Peter Huntsman purchased 100,000 shares on the open market at $9.81, investing $981,000 of personal capital. More importantly, this wasn't an isolated act of optimism. It represents his fifth meaningful open-market purchase in roughly eighteen months, following several earlier buys and additional insider accumulation by CFO Philip Lister.

Coincidence?

Perhaps.

Confidence?

Much more likely.

Meanwhile, Wall Street continues treating Huntsman like a tired commodity chemical producer despite a pending $12.5 billion merger of equals with Olin Corporation, one expected to unlock more than $400 million of identified synergies, strengthen vertical integration, and potentially reshape the company's earnings power for years to come.

At FUNanc1al, we love asking one simple question:

What if the market is still pricing yesterday's company while management is already investing in tomorrow's one?

🚀 FUNanc1al Atomic Statements

🧪 Atomic Statement #1

"Markets routinely overvalue today's earnings while undervaluing tomorrow's capital allocation." — FUNanc1al Research

🧪 Atomic Statement #2

"A merger creates headlines. Superior capital allocation creates shareholder returns." — FUNanc1al Research

🧪 Atomic Statement #3

"When management buys while Wall Street hesitates, somebody is almost certainly working from a different spreadsheet." — FUNanc1al Research

🕵️ Trigger #1: Follow the Money

The first pillar of the investment thesis is wonderfully simple.

Management is buying.

Lots of executives talk confidently during conference calls.

Far fewer reach for their personal checkbooks afterward.

Peter Huntsman just did.

His latest purchase follows several substantial open-market acquisitions during the past eighteen months, steadily increasing an already meaningful ownership position.

Even Huntsman's CFO joined the buying spree last November.

That doesn't guarantee future returns.

But it certainly suggests management believes intrinsic value sits comfortably above today's stock price.

Insiders know more about customer demand, production pipelines, integration planning and internal cost initiatives than anyone outside the building.

Their purchases deserve attention.

Especially repeated ones.

🤝 Trigger #2: The Real Story Isn't Chemicals—It's Transformation

Most investors still view Huntsman as a cyclical chemical manufacturer.

That's becoming outdated.

The real story is the proposed merger of equals with Olin Corporation, announced earlier this year.

Together, the combined company would generate roughly:

🧪 $12.5 billion in annual revenue

💰 More than $400 million of identified cost synergies

🏭 Greater vertical integration

🌎 Expanded geographic reach

⚙️ Stronger purchasing power

📈 Improved cash-flow potential

The strategic logic is compelling.

Olin brings upstream feedstocks, chlorine production and chlor-alkali operations.

Huntsman contributes downstream specialty chemicals, polyurethanes and advanced materials.

Instead of buying critical raw materials from outside suppliers, much of the value chain becomes internal.

That generally improves margins.

It reduces volatility.

It strengthens pricing power.

And it often produces exactly what investors love most:

More predictable cash flow.

As management itself noted, the combined company should also benefit from approximately $125 million in cash tax benefits, alongside operational efficiencies expected to materialize over several years.

That's real economic value—not accounting magic.

📈 Trigger #3: The Market Is Pricing Huntsman Like None of This Exists

Valuation is where the story becomes especially interesting.

Current multiples remain remarkably depressed:

📉 Price/Sales: 0.29x

🏦 Price/Book: 0.64x

🏭 Enterprise Value/Revenue: 0.59x

💵 Dividend Yield: roughly 3.5%

The market is effectively valuing Huntsman's annual revenue at 29 cents on the dollar.

Its net assets?

About 64 cents on the dollar.

Of course, book value isn't cash sitting inside a vault waiting to be distributed.

Factories aren't sold overnight.

Chemical plants don't magically become ATM machines.

Still...

When an industrial company trades materially below book value while management keeps buying shares and a transformational merger approaches, investors should probably spend more than thirty seconds looking at the opportunity.

🏛️ Trigger #4: Wall Street Has Quietly Moved In

One statistic initially looks impossible.

Institutional ownership exceeds 100%.

Even more remarkable:

Institutions collectively report ownership of approximately 107.5% of the public float.

No, Wall Street hasn't discovered parallel universes.

This happens because of securities lending, short selling and reporting mechanics that allow the same shares to appear multiple times across institutional filings.

The important takeaway isn't the math.

It's the message.

Large professional investors are heavily involved.

Among them:

• BlackRock

• Vanguard

• Hedge fund AQR Capital Management (quants are in the house)

• T. Rowe Price

• Dimensional

• Invesco

• Pzena

That's basically the investment equivalent of discovering half the neighborhood's master chefs shopping at the same grocery store.

It doesn't guarantee dinner will taste amazing...

...but it certainly gets your attention.

Meanwhile, approximately 10.5% of the float remains sold short, representing more than 17 million shares.

That's not meme-stock territory.

But if business fundamentals improve following merger integration, those short positions could eventually become future buyers.

For Huntsman (HUN)’s Institutional Ownership breakdown, 🔍 see here.

📊 Trigger #5: Earnings Are Quietly Improving

The latest quarterly results weren't spectacular.

But they were encouraging.

Revenue climbed 14% year over year to $1.66 billion, beating expectations.

Adjusted EBITDA increased dramatically from $74 million to $120 million.

Adjusted losses narrowed substantially.

Construction markets remain soft.

European energy costs remain painful.

Free cash flow remains negative.

None of those issues should be ignored.

Yet the broader trend appears to be moving in the right direction.

Revenue is growing.

Margins are stabilizing.

Industrial demand is gradually recovering.

That's precisely what investors hope to see before a major integration begins.

Sometimes turnarounds don't start with explosive profits.

They start by becoming less bad every quarter.

And yes...

That's actually progress.

👉 Want the full picture? Dive into Huntsman (HUN)'s financials here.

🎯 The FUNanc1al Verdict

At first glance, Huntsman looks like another cyclical chemical company struggling through weak construction markets, volatile energy prices and uneven earnings.

Look closer, however, and a different picture begins to emerge.

This is no longer simply a commodity chemicals story.

It's a capital allocation story.

It's a merger integration story.

And perhaps most importantly, it's a valuation story.

The market is currently valuing Huntsman at just 0.29x sales and 0.64x book value, despite management repeatedly buying shares and preparing for one of the industry's largest strategic combinations in years.

Will everything go perfectly?

Almost certainly not.

Large mergers are messy.

Synergies take time.

Industrial cycles rarely move in straight lines.

But if management executes reasonably well and the projected cost savings materialize, today's valuation could ultimately prove far too pessimistic.

For patient investors willing to tolerate volatility, Huntsman increasingly resembles a classic turnaround opportunity rather than a permanently impaired business.

As always, position sizing matters.

Turnarounds reward patience...

...and occasionally punish overconfidence.

😂 A Dash of Chemical Humor

🧪 Peter Huntsman's Timing

Most CEOs express confidence by saying,

"We're optimistic about the future."

Peter Huntsman apparently prefers saying,

"Hold my checkbook."

Buying nearly $1 million worth of stock immediately after earnings is certainly one way to get shareholders' attention.

🧪 107% Institutional Ownership

Institutional ownership exceeding 100% always sounds like Wall Street accidentally photocopied reality.

Fortunately, it's simply a by-product of securities lending.

Still...

When more than 100% of the reported float appears spoken for, finding available shares can occasionally become about as easy as finding free parking in Manhattan on Christmas Eve.

📌 Signal Extract

"Markets routinely overvalue today's earnings while undervaluing tomorrow's capital allocation."

🎯 High-Conviction Takeaway

"When management buys while Wall Street hesitates, somebody is almost certainly working from a different spreadsheet."

⚡ Quick Take (TL;DR)

Bull Case

✅ CEO continues buying shares with personal capital.

✅ Proposed $12.5B merger fundamentally changes Huntsman's long-term economics.

✅ More than $400M in identified synergies.

✅ Trading around 0.64x book value.

✅ Roughly 3.5% dividend yield while investors wait.

✅ Revenue and EBITDA trends are improving.

Bear Case

⚠️ Construction markets remain weak.

⚠️ Commodity chemical businesses remain cyclical.

⚠️ Cash flow remains negative.

⚠️ Net debt leverage ratios have remained high (around 5.0x or higher), driven by cyclically weak earnings rather than aggressive new borrowing.

⚠️ Merger execution carries operational risk and integration benefits may take years to fully materialize.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

❓ Frequently Asked Questions

Is Huntsman a value stock?

Yes.

Trading below book value and below one-third of annual sales places Huntsman firmly within traditional deep-value territory. Whether that value is ultimately realized depends largely on execution and industry conditions.

Why is the CEO buying stock?

Only Peter Huntsman knows with certainty.

However, repeated open-market purchases generally indicate management believes shares are undervalued relative to long-term intrinsic value.

Why is institutional ownership above 100%?

This results primarily from securities lending and reporting mechanics associated with short selling. It does not mean more shares physically exist than were issued.

Is the dividend safe?

The dividend currently appears supported, although investors should continue monitoring cash generation throughout the merger integration process.

What's the biggest catalyst?

The proposed merger with Olin.

If successfully completed, the combination could significantly improve scale, vertical integration, cost efficiency and long-term earnings power.

🍽️ Food for Thought: The Cross-Hub Connection

At first glance, chemicals and behavioral finance seem worlds apart.

They're not.

Both reward investors who understand reactions instead of appearances.

Markets often anchor on today's disappointing earnings while overlooking tomorrow's improved economics.

People do something remarkably similar in everyday life.

We judge situations based on their current discomfort rather than their future trajectory.

Whether evaluating companies, careers or relationships, perhaps the better question isn't:

"How does this look today?"

Instead ask:

"What happens if today's temporary headwinds disappear?"

Sometimes the greatest opportunities emerge precisely because everyone else has stopped asking that question.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al—part market analyst, part storyteller, part accidental comedian.

A longtime investor, entrepreneur, and venture-builder across technology, biotech, and fintech, he combines rigorous research with behavioral finance and a touch of humor to help readers laugh, learn, live better lives, and invest a little wiser.

When he isn't decoding insider purchases or poking fun at earnings calls, he's building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

📝 Editorial Note

Every FUNanc1al article is grounded in human research, analysis, and editorial judgment. Modern AI tools may assist with research organization, editing, and presentation, but every opinion, conclusion, rating, and recommendation remains subject to human oversight and responsibility.

To learn more about how we research, write, and review every article, please visit our Editorial Process page.

At FUNanc1al, our objective is not to predict the future with certainty, but to encourage thoughtful analysis, healthy skepticism, long-term thinking, and a smile whenever possible.